Search the Newsreel

Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth

Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S reported strong Q2 2026 results, with total revenue more than doubling year-over-year due to increased demand for its TransCon-based therapies. Yorvipath and Yuviwel showed significant growth and early momentum, respectively, contributing to the company's positive financial outlook. Ascendis also outlined pipeline …

Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost

Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results Webcast

Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale

Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

Ascentage Pharma Group International will participate in the Evercore ISI 2nd Annual China Biotech Summit in Shanghai, Pudong from August 17-19, 2026. Management will engage in a fireside chat on August 18, 2026, and conduct one-on-one investor meetings. The company is a global biopharmaceutical …

Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts

Ascendis Pharma Reports Second Quarter 2026 Financial Results

Ascendis Pharma announced strong financial results for Q2 2026, with total product revenue reaching €315 million, a 105% year-over-year increase, driven by YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company reported a net profit of €207 million and significant pipeline advancements, including long-term data for YORVIPATH, …

Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments

Ascendis Pharma A/S Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S announced strong Q2 2026 financial results, with total revenue more than doubling year-over-year to €339 million, driven by robust demand for their TransCon products, YORVIPATH, YUVIWEL, and SKYTROFA. The company reiterated its long-term growth targets, including €5 billion in revenue by …

TerrAscend Corp. (TSE:TSND): When Will It Breakeven?

Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price

Ascendis Pharma A/S has granted 15,060 warrants to employees, with an exercise price of US $254.57 per share, matching the closing price on the grant date of August 11, 2026. These warrants vest over time, with 25% vesting after one year and the remainder …

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past five years, achieving an average annual return of 17.21%. A $100 investment in ASND five years ago would now be worth $212.53, demonstrating the power of compounded returns. The article highlights the significant …

Why TerrAscend Corp. stock is rising today

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275

Morgan Stanley has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its target price at $275. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.

Ascentage Pharma Group International (SEHK:6855) Adds Global Dealmakers As Fair Value Debate Builds

(ASND) Volatility Zones as Tactical Triggers

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND), highlighting a mid-channel oscillation pattern and a strong 27.6:1 risk-reward setup. It provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report identifies positive …

Ascentage Pharma Group International (AAPG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ascentage Pharma Group International (AAPG), highlighting that 9 analysts currently recommend a "Buy" rating with a target price indicating a significant upside. The report includes current stock performance and a peer comparison, but notes that specific financial …

TerrAscend Posts Higher Q2 Revenue, Boosts Cash Flow and Extends Debt Maturities

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Time to Buy?

TerrAscend Corp. 2026 Q2 - Results - Earnings Call Presentation (TSX:TSND:CA) 2026-08-06

Ascendis Pharma (ASND) Could Be 20% Undervalued Following Its Recent Pullback

Ascendis Pharma (ASND) has experienced a recent pullback, with its stock down about 9% over the past month. Despite this, a common valuation narrative suggests the company is 19.8% undervalued, with a fair value of $304.60 compared to its current share price of $244.20. …

Ascendis plans Aug. 13 webcast before U.S. markets open

Ascendis Pharma (Nasdaq: ASND) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the U.S. market opens. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with a …

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Pharma A/S announced it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before U.S. financial markets open. The company will also host a conference call and live webcast on the same day at …

TerrAscend Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Why TerrAscend Corp. stock is skyrocketing today

Ascentage Pharma Group International - ADR (AAPG) News, Articles, Events & Latest Updates

This article compiles recent news and updates concerning Ascentage Pharma Group International - Unsponsored ADR (AAPG). Several reports from Zacks and MarketBeat highlight Wall Street analysts' predictions of significant upside potential for AAPG, ranging from 152.23% to 160.09%. Other news items cover fluctuations in …

Ascendis Pharma (ASND) reports new TransCon CNP achondroplasia trial data

Ascendis Pharma (ASND) has reported positive new data from its Phase 2 COACH trial for achondroplasia, demonstrating durable growth in children treated with a combination of TransCon CNP and TransCon hGH. The combination therapy achieved annualized growth velocity at or above the 97th percentile, …

CapitaLand Ascendas REIT (SGX:A17U) Stock Gains Lean On One Off Profit

Ascendis Announces COACH Week 78 Results and Provides

Ascendis Pharma announced positive 78-week results from its COACH trial for achondroplasia, showing durable, proportional growth with combination therapy (TransCon CNP + TransCon hGH). The company also provided an update on YUVIWEL (TransCon CNP) uptake in the U.S. and highlighted durable benefits from TransCon …